sub:assertion {
d:DB00970 v:identifier "DB00970" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB00970" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB00970> ;
dv:drugbank-id "APRD00124" , "DB00970" ;
dv:x-ahfs <
http://bio2rdf.org/ahfs:10:00.00> ;
dv:x-atc <
http://bio2rdf.org/atc:L01DA01> ;
dv:x-bindingdb <
http://bio2rdf.org/bindingdb:50023797> ;
dv:x-cas <
http://bio2rdf.org/cas:50-76-0> ;
dv:x-chebi <
http://bio2rdf.org/chebi:27666> ;
dv:x-dpd <
http://bio2rdf.org/dpd:213071> ;
dv:x-kegg <
http://bio2rdf.org/kegg:C06770> , <
http://bio2rdf.org/kegg:D00214> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA151917012> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Dactinomycin> ;
dct:description "A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)"@en ;
dct:identifier "drugbank:DB00970" ;
dct:title "Dactinomycin"@en ;
a dv:Drug ;
rdfs:label "Dactinomycin [drugbank:DB00970]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB00970> , <
http://www.drugs.com/cdi/dactinomycin.html> , <
http://www.rxlist.com/cgi/generic2/dactinomycin.htm> .
}